keyboard_arrow_up

EGF-R Antibodies - Biosimilars and Biosuperiors

Reportstack has announced a new market research publication on EGF-R Antibodies - Biosimilars and Biosuperiors which provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies.

The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

To view the table of contents and know more details please visit EGF-R Antibodies - Biosimilars and Biosuperiors report.